source
- Ultragenyx to consider major cost cuts after Angelman drug fails trialUltragenyx announced that its experimental therapy GTX-102 (apazunersen) for Angelman syndrome failed to meet primary and secondary endpoints in a Phase 3 study. The company said there were no dif…
- Revolution Medicines' Rasonque shows 42% response and 16-month survival in NSCLC subgroupData from a subgroup of an earlier trial, described by Truist Securities as the most relevant to Revolution Medicines' ongoing Phase 3 study, reported a 42% overall response rate and a median overa…